Efficacy and safety of repetitive transcranial magnetic stimulation in the treatment of male smokers with tobacco use disorder: a randomized controlled trial by Salma W. Mousa, Adel A. Badawy, Gehan F. Attia, Wesam A. Ghareeb

“…Further research is needed to optimize treatment protocols, explore combined therapies, and assess long-term outcomes to improve smoking cessation in diverse populations.…”
Get full text

Congestive heart failure adherence redesign trial: a pilot study by Ashvarya Mangla, Rami Doukky, Lynda H Powell, Elizabeth Avery, DeJuran Richardson, James E Calvin

“…We hypothesised that providing individualised self-management support to patients and feedback on use of evidence-based HF therapies (EBT) to physicians could lead to improvements in care and decrease hospitalisations. …”
Get full text

Assessment of the healing properties of Cichorium intybus L. extracts on wounds by Berivan Kaçmaz, Duygu Misirli, Seçil Erden Tayhan, Zafer Ömer Özdemir, Mahfuz Elmastaş

“…Further investigation into active chemicals and mechanisms contributing to its wound healing properties is needed, potentially leading to advancements in wound healing therapies.…”
Get full text

Transitioning from wet lab to artificial intelligence: a systematic review of AI predictors in CRISPR by Ahtisham Fazeel Abbasi, Muhammad Nabeel Asim, Andreas Dengel

“…This groundbreaking technology holds immense potential for the development of targeted therapies for a wide range of diseases, including cancers, genetic disorders, and hereditary diseases. …”
Get full text

Phytomedicine nanoformulations for Parkinson's disease by Chinthu V. Saji, K P Mohanakumar, Rajesh A Shenoi

“…This highlights the need for disease-modifying therapies. In recent years, attentions of both clinicians and patients have shifted to herbal medicines that are rich source of bioactive compounds with therapeutic potential to target multiple pathways involved in PD pathology. …”
Get full text

Tools used to measure quality of life in adults with cystic fibrosis– a systematic review by Dorota Snop-Perkowska, Jakub Świtalski, Katarzyna Wnuk, Paweł Olszewski, Anna Augustynowicz

“…Abstract Background Measuring the quality of life in patients with cystic fibrosis is important, both in terms of assessing the implementation of new therapies and monitoring their effects, as well as the ongoing evaluation of patients’ condition. …”
Get full text

Optimizing therapeutic outcomes: preconditioning strategies for MSC-derived extracellular vesicles by Yuqi Song, Fengrui Liang, Weikun Tian, Erin Rayhill, Liping Ye, Xinghan Tian

“…Despite the potential of MSC-EVs, this review also acknowledged the limitations of traditional MSC therapies and advocates for a strategic pivot towards exosome-based modalities to enhance therapeutic outcomes. …”
Get full text

NT5E (CD73) as a prognostic biomarker and therapeutic target associated with immune infiltration in lung adenocarcinoma by Leyan Chen, Tuoya Qi, Bishu Zhang, Xuelong Wang, Mingfeng Zheng

“…Additionally, drug sensitivity analysis highlights the potential of selumetinib and PD318088, both MEK1/2 inhibitors, to target NT5E in LUAD treatment, suggesting their use as single agents or in combination with other therapies. Collectively, these findings establish NT5E as a promising prognostic biomarker and therapeutic target in LUAD, particularly in the context of immune cell infiltration.…”
Get full text

Silica Nanoparticles Loaded With Selenium Quantum Dots Reduce Myocardial Ischemia-Reperfusion Injury by Alleviating Ferroptosis and Mitochondrial Dysfunction by Li T, Yang B, Liu X, Shi D, Wang Z, Chen Y, Shen C

“…Despite extensive research, no clinical therapies effectively target ferroptosis in IR injury. …”
Get full text

Estimating the Health-Related Quality of Life Benefit of Prophylactic Treatment for COVID-19 in Immunocompromised People: A Multimethod Valuation Study by Katy Gallop, Rebekah Hall, Michael Watt, Daniel Squirrell, Neil Branscombe, Sofie Arnetop, Andrew Lloyd

“…**Objective:** To estimate the potential HRQoL and utility benefit of PrEP for prevention of COVID-19 in individuals with IC conditions who may not have an adequate response of full vaccination (and therefore are at “highest risk” of severe COVID-19) that can be used in future economic evaluations of preventative therapies against COVID-19. **Methods:** Vignettes describing HRQoL associated with 2 pre-PrEP states (shielding and semi-shielding behavioral restrictions) and a post-PrEP state were developed from a literature review and tested through interviews with clinicians (n = 4) and individuals with IC conditions (n = 10). …”
Get full text

Rauwolfia vomitoria- a promising medical plant for benign prostatic hyperplasia management; yet with challenges by George Awuku Asare, Perpetua Dagadu, Samuel Adjei, Bernice Asiedu, Samkeliso Takaidza, Vivash Naidoo, Brodrick Amoah, Ifeoma Celestina Orabueze, Kwasi Bugyei

“…Although conventional allopathic treatments are widely used for managing BPH, they are frequently associated with adverse side effects, prompting a global shift toward natural and alternative therapies. This study aims to investigate the therapeutic effects of Rauwolfia vomitoria Aqueous Root Extract (RVARE) as a potential natural oral treatment for BPH. …”
Get full text

EDF1 accelerates ganglioside GD3 accumulation to boost CD52-mediated CD8+ T cell dysfunction in neuroblastoma by Di Li, Meng Li, Zhenjian Zhuo, Huiqin Guo, Weixin Zhang, Yile Xu, Hai-Yun Wang, Jiabin Liu, Huimin Xia, Huiran Lin, Jue Tang, Jing He, Lei Miao

“…Modulating NB-associated GD3 levels through metabolic intervention is beneficial for tuning the depth and duration of responses to current NB therapies. The integration of transcriptomic and lipidomic data offers a more comprehensive understanding of the interaction between LacCer metabolites and the immune status in NB. …”
Get full text

TOURISM study (Treatment Outcomes in UteRIne SarcoMa): a 10-year retrospective evaluation of practice in the UK by Rebekah Webb, Mohammed Al-Zubaidi, Mark A Baxter, Karin Purshouse, James Robertson, Helen Creedon, Katherine Fair, Asma Sarwar, Laura Hannington, Adam L Peters, Samuel Mcinerney, Karen E Mactier, Georgina E Wood, Mai K Bishr, Leonie Eastlake, Katharine Lankester, Alison L Stillie

“…These data highlight the importance of a multidisciplinary approach and describe real-world trends in systemic therapies, radiotherapy and surgical treatment in this rare cancer type.…”
Get full text

UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model by Jacqueline Palace, Martin Duddy, Thomas Bregenzer, Mike Boggild, Joel Oger, Helen Tremlett, Charles Dobson, Fheng Zhu

“…Objectives In 2002, the UK's National Institute for Health and Care Excellence concluded that the multiple sclerosis (MS) disease modifying therapies; interferon-β and glatiramer acetate, were not cost effective over the short term but recognised that reducing disability over the longer term might dramatically improve the cost effectiveness. …”
Get full text

Plasma Iron Levels at Early Breast Cancer Diagnosis Are Associated With Development of Secondary Metastases: A Single-Center Retrospective Cohort Study by Jasmine De Troy, Sarah-Maria Fendt, Sigrid Hatse, Patrick Neven, Ann Smeets, Annouschka Laenen, Hans Wildiers

“…Further research is needed to understand the underlying mechanisms and to explore the potential of iron-targeted therapies.…”
Get full text

Multiple Comorbidities, Psychiatric Disorders, Healthcare Resource Utilization and Costs Among Adults with Essential Tremor: A Retrospective Observational Study in a Large US Comme... by Dingwei Dai, Ali Samiian, Joaquim Fernandes, Henriette Coetzer

“…In the 12 months following the index date, 26.0% of patients had no insurance claims for ET-related pharmacotherapy or invasive therapies. Patients with ET had a higher number of comorbidities than non-ET patients (5.3 \[3.2\] vs 4.0 \[3.3\]); a higher prevalence of psychiatric disorders (depression: 25.6% vs 15.3%; adjusted odds ratio (AOR) \[95% CI\], 1.56 \[1.41-1.73\]; anxiety: 27.7% vs 15.5%, AOR: 1.78 \[1.61-1.96\]); and higher total healthcare costs: $17 560 \[$39&#8239;972\] vs $13&#8239;237 \[$27&#8239;098\], adjusted cost ratio \[95% CI\]: 1.11 \[1.06-1.16\]; all _P_<.0001. …”
Get full text

The heterogeneity of NOTCH1 to tumor immune infiltration in pan-cancer by XiaoJun Duan, Rihan Wu, Mingyang Zhang, Kexin Li, Lei Yu, Huirong Sun, Xingxia Hao, Changshan Wang

“…Pharmacological regulation of NOTCH1 is promising in tumor immunotherapy, whereas the effective rate of existing therapies remains low. NOTCH1 functions, as a cancer suppressor or a cancer promoter in different cancers, is engaged in the crosstalk between the immune microenvironment and cancer cells, posing a major challenge to immunotherapy. …”
Get full text

Perceptions in 3.6 Million Web-Based Posts of Online Communities on the Use of Cancer Immunotherapy: Data Mining Using BERTopic by Xingyue Wu, Chun Sing Lam, Ka Ho Hui, Herbert Ho-fung Loong, Keary Rui Zhou, Chun-Kit Ngan, Yin Ting Cheung

“…Six themes were identified, primarily covering (1) hopeful prospects offered by immunotherapy, (2) perceived effectiveness of immunotherapy, (3) complementary therapies or self-treatments, (4) financial and mental impact of undergoing immunotherapy, (5) impact on lifestyle and time schedules, and (6) side effects due to treatment. …”
Get full text

Epidemiology of clinically significant migraine in Israel: a retrospective database study by A. Shifrin, E. Domany, M. Tirosh, D. Davidovici, S. Vinker, I. Forschner, A. Israel

“…Clinically significant migraine patients were identified using stringent criteria, including repeated diagnostic codes for migraine, confirmation by a neurologist, or the use of migraine-specific therapies. Each migraine patient was matched 1:1 with a control individual of similar age, sex, socioeconomic status, and ethnic background. …”
Get full text

The Association of Retinal Disease with Vision Impairment and Functional Status in Medicare Patients by Vincent Garmo, Xiaohui Zhao, Carmen D. Ng, Aimee Near, Tania Banerji, Keiko Wada, Gary Oderda, Diana Brixner, Joseph Biskupiak, Ferhina S. Ali, Archad M. Khanani, Alicia Menezes, Ibrahim M. Abbass

“…**Conclusions:** Patients with nAMD continue to experience more vision impairment and worse functional status compared with a similar population of Medicare beneficiaries despite availability of therapies like antivascular endothelial growth factor to treat retinal disease.…”
Get full text